API | echothiophate

echothiophate (phospholine iodide) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW

Echothiophate is a potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia. Echothiophate iodide for ophthalmic solution will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eye drop therapy by binding irreversibly to cholinesterase, and thus long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation. ^NCATS

Chemistry

SMILES: CCOP(=O)(OCC)SCC[N+](C)(C)C
InChIKey: BJOLKYGKSZKIGU-UHFFFAOYSA-N
Mol. Mass: 256.33
ALogP: 2.61 Partition coefficient
ChEMBL Molecules:

echothiophate

echothiophate iodide

More Chemistry

Pharmacology

Mechanism of Action:
- Acetylcholinesterase (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Topical
Pro Drug: No

Organizations (3)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (2)

Esotropia (approved 1960)

Glaucoma, Open-Angle (approved 1960)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Myopia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue